Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis
-
- Imafuku Tadashi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Tanaka Motoko
- Department of Nephrology, Akebono Clinic
-
- Tokunaga Koki
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Miyamura Shigeyuki
- Faculty of Pharmaceutical Sciences, Sojo University
-
- Kato Hiromasa
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Tanaka Shoma
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Nakano Takehiro
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Hirata Kenshiro
- Faculty of Pharmaceutical Sciences, Sojo University
-
- Kadowaki Daisuke
- Faculty of Pharmaceutical Sciences, Sojo University
-
- Maeda Hitoshi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Matsushita Kazutaka
- Department of Nephrology, Akebono Clinic
-
- Otagiri Masaki
- Faculty of Pharmaceutical Sciences, Sojo University
-
- Komaba Hirotaka
- Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine
-
- Fukagawa Masafumi
- Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine
-
- Watanabe Hiroshi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Maruyama Toru
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
Search this article
Description
<p>Chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) have an increased risk of cardiovascular disease (CVD). Cinacalcet is a calcimimetic that permits impaired endothelial functions to be recovered via inhibiting parathyroid hormone (PTH) production in SHPT patients. However, the underlying mechanism for its action remains unknown. The purpose of this study was to examine the effect of cinacalcet on the redox state of human serum albumin (HSA), a reliable marker for assessing endothelial oxidative damage in SHPT patients who were receiving hemodialysis. Cinacalcet was administered to six SHPT patients for a period of 8 weeks. After 4 weeks of treatment, cinacalcet significantly decreased the oxidized albumin ratio which is a ratio of reduced and oxidized forms of HSA via increasing reduced form of HSA. Moreover, the radical scavenging abilities of HSA that was isolated from SHPT patients were increased by cinacalcet, suggesting the recovery of the impaired vascular anti-oxidant ability. Interestingly, the oxidized albumin ratio in SHPT patients was significantly higher than that in hemodialysis patients. In addition, the changes of intact PTH levels were significantly correlated with the oxidized albumin ratio. It therefore appears that PTH may induce oxidative stress in SHPT patients. In fact, an active analogue of PTH increased the production of reactive oxygen species in human endothelial cells. Thus, cinacalcet exhibits anti-oxidative activity through its pharmacological action. Additionally, cinacalcet itself showed radical scavenging activity. In conclusion, cinacalcet improves the redox status of HSA by inhibiting PTH production and partially by its radical scavenging action.</p>
Journal
-
- Biological and Pharmaceutical Bulletin
-
Biological and Pharmaceutical Bulletin 43 (10), 1583-1590, 2020-10-01
The Pharmaceutical Society of Japan
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390004222630339968
-
- NII Article ID
- 130007920876
-
- NII Book ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL BIB ID
- 030662734
-
- PubMed
- 32999168
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- PubMed
- CiNii Articles
- KAKEN
- OpenAIRE
-
- Abstract License Flag
- Disallowed